Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$100,000.00

Development & evaluation of liposomal TLR7 agonist combined with immunotherapeutic antibodies for treating pancreatic cancer

FY 2019-20

Summary
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world with high mortality (< 8% survival rate beyond 5 years following diagnosis) due to poor prognosis and limited treatment options. The PDAC tumor microenvironment is highly immunosuppressive, associated with inactive T-cell functionality, thereby rendering it difficult to be treated by conventional immunotherapies and/or chemotherapies. Our preliminary data show that the combination therapy of toll-like receptor agonist such as resiquimod (RMD) loaded nanoparticles (NPs) along with therapeutic antibodies (aCD40+aCTLA-4+aPD-1, abbreviated as CP4) can regress both local and distant tumors in a highly metastatic, multi-site implanted mouse pancreatic cancer (Kras+/LSL-G12D; Trp53+/LSL-R172H; Pdx1-Cre model: KPC) model, clinically relevant to PDAC. Using ultrasound to increase the tumor temperature, we can release RMD in the tumor. However, our current RMD-NPs release the cargo within 1 hour at 37°C and this reduces the tumor exposure. The first part of this research will focus on developing a stable temperature-sensitive RMD-NP formulation, in order to deliver the payload safely with maximal therapeutic efficacy combined with CP4. This will be followed by characterizing their impact on the tumor immune microenvironment, with comprehensive bioanalytical assays and medical imaging techniques, to predict the activity against PDAC.
Program
CIHR Fellowship
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
412388
Name
Tang Wei-Lun
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Development & evaluation of liposomal TLR7 agonist combined with immunotherapeutic antibodies for treating pancreatic cancer
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Biomedical Imaging; Cancer Immunotherapy; Pancreatic Cancer; Small Drug Delivery; Targeted Therapy; Therapeutic Antibodies
Abstract
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world with high mortality (< 8% survival rate beyond 5 years following diagnosis) due to poor prognosis and limited treatment options. The PDAC tumor microenvironment is highly immunosuppressive, associated with inactive T-cell functionality, thereby rendering it difficult to be treated by conventional immunotherapies and/or chemotherapies. Our preliminary data show that the combination therapy of toll-like receptor agonist such as resiquimod (RMD) loaded nanoparticles (NPs) along with therapeutic antibodies (aCD40+aCTLA-4+aPD-1, abbreviated as CP4) can regress both local and distant tumors in a highly metastatic, multi-site implanted mouse pancreatic cancer (Kras+/LSL-G12D; Trp53+/LSL-R172H; Pdx1-Cre model: KPC) model, clinically relevant to PDAC. Using ultrasound to increase the tumor temperature, we can release RMD in the tumor. However, our current RMD-NPs release the cargo within 1 hour at 37°C and this reduces the tumor exposure. The first part of this research will focus on developing a stable temperature-sensitive RMD-NP formulation, in order to deliver the payload safely with maximal therapeutic efficacy combined with CP4. This will be followed by characterizing their impact on the tumor immune microenvironment, with comprehensive bioanalytical assays and medical imaging techniques, to predict the activity against PDAC.
Competitiondate
201910
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Tang, Wei-Lun
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~
Direct Payment - $100,000 Grant (2019-20) | Canada Spends